Shire Partnering Day
|
Shire, one of the world's leading specialty biopharmaceutical companies, is fully focused on a single purpose: to enable people with life-altering conditions to lead better lives. Through our Shire Human Genetic Therapies (HGT) business, we pursue opportunities on behalf of patients and families facing such rare diseases as Fabry disease, Hunter syndrome, Gaucher disease, hereditary angioedema, and metachromatic leukodystrophy—patients whose very lives often hinge on the discovery and delivery of extraordinary medicines. Through our Specialty Pharma business, meanwhile, we develop and distribute an innovative portfolio of treatments for patients with ADHD, ulcerative colitis, and end-stage renal disease. Our commitment throughout is on symptomatic diseases, treated by specialist physicians. We take the risks we need to take, so that we might change lives for the discernible better. |
Partnering Areas of Interest
CNS • GI • Orphan Diseases |
Why Partner with Shire?
Strategic partnerships have fueled Shire’s rapid growth—acquisitions and mergers designed to fortify development as well as marketed portfolios. Consequently all collaborative opportunities are managed in a rapid and responsible manner. To facilitate this, Shire’s business development team benefits from direct access to internal expertise across the full range of product development functions from initial scientific review through to full commercial evaluation.
To any prospective partner, Shire offers
- A highly experienced executive management team, that importantly, for a company of Shire’s size and growth, retains a flexible and creative approach to collaborations
- Experienced Sales and Marketing capabilities in the leading World markets, focused upon specialty physicians, patients, and payers
- Proven product development and regulatory capabilities
- Objective and rapid response to partnering opportunities
- A results driven culture
Shire’s BD team welcomes approaches from organizations with products, technologies or projects that fit with our areas of interests.
Confirmed Shire Participants
|
Mindy Brooks, PhD West Coast Scout/Consultant |
Barbara Deptula Executive Vice President and Chief Corporate Development Officer |
|
Jennifer King, Ph.D. Senior Director, Scientific Licensing |
Brian Piper Senior Director, Strategic Investment Group |
|
Greg Robinson, Ph.D. Senior Director, Scientific Licensing |
Jonathan Rubin, Ph.D., MBA Scientific Licensing |
|
Arthur Tzianabos Vice President and Head of Research |
|
![]() |
*Event registration fees are due once confirmed for one-on-one partnering meeting and can be applied toward first year's membership if company joins within 30 days of partnering event.
Please contact Misha Tsirulnikov at misha@baybio.org or 650-871-7101 x205 for further information.
Is your company a member? Click here to check.
See how your company can save money by becoming a BayBio member!
End Date: Oct 6, 2011. 04:30 PM
Cost: Breakfast Only Free to Attend Partnering BayBio Members: Free | Non-Members:$500*









































